GlassScriptPhysician profile
Douglas A Burd
NPI 1851330682
$3,514.81
in general payments reported to CMS, 2019-2025
24 companies · $133 in 2025
The $133 reported for 2025 was more than what a typical Diagnostic Radiology provider received nationally (typical 2025 total: $112).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2020: $54.50 · 2021: $113 · 2022: $485 · 2023: $481 · 2024: $1,899 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,750 · Food and Beverage: $764.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,750.00 |
| Food and Beverage | $764.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $1,750.00 | 2024 | Encor |
| Merck Sharp & Dohme LLC | $210.68 | 2019-2023 | Keytruda |
| Bayer Healthcare Pharmaceuticals INC. | $205.69 | 2022-2025 | |
| Seagen INC. | $196.96 | 2020-2023 | Padcev |
| E.R. Squibb & Sons, L.L.C. | $139.07 | 2019-2023 | Opdivo |
| Exelixis INC. | $125.24 | 2022-2023 | Cabometyx |
| Astrazeneca Pharmaceuticals LP | $124.54 | 2023-2025 | Imfinzi, Enhertu, Lynparza |
| Incyte Corporation | $117.84 | 2019-2023 | Jakafi |
| Eisai INC. | $98.15 | 2023-2024 | |
| Amgen INC. | $89.80 | 2021-2022 | |
| Janssen Biotech, INC. | $70.78 | 2019-2025 | Akeega, Erleada |
| Ge Healthcare | $60.48 | 2023 | |
| Pfizer INC. | $41.13 | 2019-2024 | |
| Glaxosmithkline, LLC. | $34.70 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $33.64 | 2024 | Libtayo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirati Therapeutics, INC. | $30.42 | 2024 | Krazati |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.79 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.98 | 2021 | |
| Alexion Pharmaceuticals, INC. | $24.98 | 2019 | |
| Gilead Sciences, INC. | $24.96 | 2023 | Trodelvy |
| Myovant Sciences INC. | $24.09 | 2022 | |
| Celgene Corporation | $22.82 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $20.00 | 2019 | |
| Lilly USA, LLC | $17.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Burd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.